The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Molecular Basis of Coronavirus Virulence and Vaccine Development
Open accessAbstract
Virus vaccines have to be immunogenic, sufficiently stable, safe, and suitable to induce long-lasting immunity. To meet these requirements, vaccine studies need to provide a comprehensive understanding of (i) the protective roles of antiviral B and T-cell-mediated immune responses, (ii) the complexity and plasticity of major viral antigens, and (iii) virus molecular biology and pathogenesis. There are many types of vaccines including subunit vaccines, whole-inactivated virus, vectored, and live-attenuated virus vaccines, each of which featuring specific advantages and limitations. While nonliving virus vaccines have clear advantages in being safe and stable, they may cause side effects and be less efficacious compared to live-attenuated virus vaccines. In most cases, the latter induce long-lasting immunity but they may require special safety measures to prevent reversion to highly virulent viruses following vaccination. The chapter summarizes the recent progress in the development of coronavirus (CoV) vaccines, focusing on two zoonotic CoVs, the severe acute respiratory syndrome CoV (SARS-CoV), and the Middle East respiratory syndrome CoV, both of which cause deadly disease and epidemics in humans. The development of attenuated virus vaccines to combat infections caused by highly pathogenic CoVs was largely based on the identification and characterization of viral virulence proteins that, for example, interfere with the innate and adaptive immune response or are involved in interactions with specific cell types, such as macrophages, dendritic and epithelial cells, and T lymphocytes, thereby modulating antiviral host responses and viral pathogenesis and potentially resulting in deleterious side effects following vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B. W., Ziebuhr, J., Szretter, K. J., Baker, S. C., Barchet, W., Diamond, M. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.1979 · Cited by 811
Continuous and Discontinuous RNA Synthesis in Coronaviruses
Sola, I., Almazán, F., Zúñiga, S., & Enjuanes, L. (2015) · Annual Review of Virology · doi:10.1146/annurev-virology-100114-055218 · Cited by 643 · cited 2×
“1) (de Groot et al., 2012; Sola et al., 2015) .”
Self-citationBolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · cited 11×
“Many vaccines based on chemically inactivated SARS-CoV virions have been evaluated in animal models such as hamsters, mice, ferrets, and NHPs (Bolles et al., 2011; Iwata-Yoshikawa et al., 2014; Roberts et al., 2010; Tseng et al., 2012) .”
BackgroundInfluentialLi, K., Wohlford-Lenane, C., Perlman, S., Zhao, J., Jewell, A. K., Reznikov, L. R., Gibson-Corley, K. N., Meyerholz, D. K., & McCray, P. B. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv499 · Cited by 459 · cited 3×
“The other type of MERS-CoV-susceptible mice available to date includes knockin strains in which 3 or 13 exons of mouse DPP4 have been replaced with the homologous sequences from hDPP4 Li et al., 2016; Pascal et al., 2015) .”
Chu, H., Zhou, J., Wong, B. H.-Y., Li, C., Chan, J. F.-W., Cheng, Z.-S., Yang, D., Wang, D., Lee, A. C.-Y., Li, C., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv380 · Cited by 448 · cited 14×
“The possibility of productive infection in macrophages (MØ) and dendritic cells (DCs) byMERS-CoV is under debate.”
BackgroundResultInfluentialChannappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K., & Perlman, S. (2014) · Journal of Virology · doi:10.1128/jvi.01505-14 · Cited by 411 · cited 2×
“It has been shown that memory CD8 + T cells specific for an immunodominant epitope substantially protected aged mice from lethal SARS-CoV infection (Channappanavar et al., 2014) .”
BackgroundTang, X.-C., Agnihothram, S. S., Jiao, Y., Stanhope, J., Graham, R. L., Peterson, E. C., Avnir, Y., Tallarico, A. S. C., Sheehan, J., Zhu, Q., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402074111 · Cited by 232 · cited 2×
“Fully human neutralizing antibodies may be developed using different technologies and applied as therapeutic or prophylactic agents (Jiang et al., 2014; Tang et al., 2014; ter Meulen et al., 2004; Ying et al., 2014; Zhang et al., 2005; Zhu et al., 2007) .”
BackgroundZhou, W., Wang, W., Wang, H., Lu, R., & Tan, W. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-433 · Cited by 124
Markusic, D. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni062 · Cited by 78 · cited 2×
“…cells were generated in which E protein expression was under the control of an optimized Tet-On system for doxycyclineinducible gene expression, drastically reducing leaky expression (Das et al., 2016; Markusic et al., 2005) and (J. Gutierrez, I. Sola, and L. Enjuanes, 2016, unpublished results).”
Cited by
Coronavirus Disease 2019–COVID-19
Dhama, K., Khan, S., Tiwari, R., Sircar, S., Bhat, S., Malik, Y. S., Singh, K. P., Chaicumpa, W., Bonilla-Aldana, D. K., & Rodriguez-Morales, A. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00028-20 · Cited by 1,876
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
Coronavirus Disease 2019: Coronaviruses and Blood Safety
Chang, L., Yan, Y., & Wang, L. (2020) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2020.02.003 · Cited by 659
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735227 · Cited by 623
Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection
Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K., Vernardis, S. I., Egger, A.-S., Kreidl, M., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.05.012 · Cited by 561
“Coronaviruses are known to actively disrupt the host immune response (Enjuanes et al., 2016).”
BackgroundA systematic review of SARS-CoV-2 vaccine candidates
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00352-y · Cited by 545
Origins and Evolution of the Global RNA Virome
Wolf, Y. I., Kazlauskas, D., Iranzo, J., Lucía-Sanz, A., Kuhn, J. H., Krupovic, M., Dolja, V. V., & Koonin, E. V. (2018) · mBio · doi:10.1128/mbio.02329-18 · Cited by 508
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 453
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Ward, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D’Aoust, M.-A., Dhaliwall, J., Finkle, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01370-1 · Cited by 360
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
Linsky, T. W., Vergara, R., Codina, N., Nelson, J. W., Walker, M. J., Su, W., Barnes, C. O., Hsiang, T.-Y., Esser-Nobis, K., Yu, K., et al. (2020) · Science · doi:10.1126/science.abe0075 · Cited by 216
Widjaja, I., Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., van Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado, R., Grosveld, F., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1597644 · Cited by 115
Self-citation
Metadata
- Authors
- Enjuanes, L., Zuñiga, S., Castaño-Rodriguez, C., Gutierrez-Alvarez, J., Canton, J., & Sola, I.
- Venue
- Advances in Virus Research
- Publisher
- Elsevier
- Published
- 2016
- Volume
- 96
- Pages
- 245-286
- ISSN
- 0065-3527 (ISSN-L)
- OpenAlex
- W2536224011
- Cited by
- 159
- References
- 12
- FWCI
- 12.23
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.